EUVIMEDEUVIMED entdecken
Crossref

Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes

Tetsuhiko Sato iD, Yoshinori Azuma, Chikafumi Ozone, Mikako Okazaki, Asami Takeda, Manabu Okada, Kenta Futamura, Takahisa Hiramitsu, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Tetsuhiko Sato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Integrated Strategic Medicine, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Aichi 4668650, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Kidney Transplantation, Renal Insufficiency. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have the potential to improve native kidney function.

Objective

This work aimed to elucidate the possible protective effects of GLP-1 RAs on kidney graft function after successful kidney transplantation (KTX).

Methods

This retrospective cohort study included all KTX recipients (KTRs) at our facility with type 2 diabetes who were followed up from 1 month post-transplantation for 24 months or longer as of December 31, 2020. We investigated associations between the use of GLP-1 RAs and other antidiabetic medications (non–GLP-1 RAs) and the risk of sustained estimated glomerular filtration rate (eGFR) reduction (40% reduction compared with baseline for 4 months) for KTRs with type 2 diabetes. We calculated the propensity score of initiating GLP-1 RAs compared with that of initiating non–GLP-1 RAs as a function of baseline covariates using logistic regression. The inverse probability of the treatment-weighted odds ratio was estimated to control for baseline confounding variables. Sodium-glucose cotransporter 2 inhibitor use was a competing event. The primary outcome was sustained eGFR reduction of at least 40% from baseline for 4 months post-transplantation.

Results

Seventy-three patients were GLP-1 RA users and 73 were non–GLP-1 RA users. Six patients and 1 patient in the non–GLP-1 RA and GLP-1 RA groups had sustained eGFR reduction. GLP-1 RA use after KTX was associated with a lower risk of sustained eGFR reduction.

Conclusion

GLP-1 RAs resulted in lower eGFR reduction compared with non–GLP-1 RAs and may contribute to better kidney graft survival after KTX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Kidney TransplantationRenal InsufficiencyHumansRetrospective StudiesHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

glucagon-like peptide 1 receptor agonistkidney functionkidney transplant recipienttype 2 diabetes

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Integrated Strategic Medicine, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Aichi 4668650, Japan.
  • Division of Diabetes and Endocrinology, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Aichi 4668650, Japan.
  • Department of Nephrology, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Aichi 4668650, Japan.
  • Department of Transplant Surgery, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Aichi 4668650, Japan.
  • Department of Transplant Nephrology, Japanese Red Cross Aichi Medical Center, Nagoya Daini Hospital, Nagoya, Aichi 4668650, Japan.

ORCID-Profile: Tetsuhiko Sato

Zitieren

APA

Sato, T., Azuma, Y., Ozone, C., Okazaki, M., Takeda, A., Okada, M., Futamura, K., Hiramitsu, T., Goto, N., Narumi, S., & Watarai, Y. (2023). Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad177

Vancouver

Sato T, Azuma Y, Ozone C, Okazaki M, Takeda A, Okada M, et al. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad177

BibTeX
@article{Sato2023,
  author = {Sato, Tetsuhiko and Azuma, Yoshinori and Ozone, Chikafumi and Okazaki, Mikako and Takeda, Asami and Okada, Manabu and Futamura, Kenta and Hiramitsu, Takahisa and Goto, Norihiko and Narumi, Shunji and Watarai, Yoshihiko},
  title = {Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad177}
}
Kostenlos starten →